Animal & PDX Models

Technology Transfer Contacts

Inna Khartchenko, MS, MBA
Director, Technology Transfer
215-214-3989
[email protected]
Natalia Shalginskikh, PhD
Licensing Associate,
Technology Transfer
267-963-7121
[email protected]
Tatiana Venkova, PhD
Licensing Associate,
Technology Transfer
215-983-0257
[email protected]

(technologies available for licensing)

Note: Links to Patents may require a browser newer than Internet Explorer 9, such as Chrome, Safari, Firefox, Edge, or Internet Explorer 11

TECH ID	TITLE	LEAD INVENTOR	CONTACT
02-20	Tg-MISIIR-TAg transgenic mice: a model of epithelial ovarian Abstract	Denise Connolly	Natalia Shalginskikh
03-39R	Ovarian Cancer Prone Mice: TgMISIIR -TAg-DR26 Abstract	Denise Connolly	Natalia Shalginskikh
06-34	Mouse model of Spontaneous Mesothelioma (Conditional Bap1 knockout mice) Abstract	Joseph Testa	Tatiana Venkova
06-37	Pak-1-KO mouse Abstract	Jonathan Chernoff	Natalia Shalginskikh
07-04	TgMISIIR-TAg-EE73 mice Abstract	Denise Connolly	Natalia Shalginskikh
98-12	PAK2 fl/fl Mouse	Jonathan Chernoff	Natalia Shalginskikh
99-19	Apc +/Min - FCCC mice: a model for colorectal cancer Abstract	Margie Clapper	Natalia Shalginskikh
211-JT	Appl1 knock out mouse Abstract	Joseph Testa	Tatiana Venkova
223-GE	TetO-p16 t Transgenic Mouse Allowing Inducible Expression of a Potent Cell Cycle Inhibitor Patent No. US8653324B2; Summary	Greg Enders	Tatiana Venkova
261-JT	Appl 1 FF mouse model Abstract	Joseph Testa	Tatiana Venkova
342-JC	p21-Activated Kinase Inhibitor Domain Targeted Transgenic Mouse (ROSA26-LSL-PID) Published Application No.; Summary	Jonathan Chernoff	Natalia Shalginskikh
405-JC	Mice with Transgene of iBox Peptide Inhibitor of Group B p21-Activated Kinases (ROSA26-LSL-iBox) Published Application No.; Summary	Jonathan Chernoff	Natalia Shalginskikh
448-DC	TgMISIIR-TAg-DQ62 mice Abstract	Denise Connolly	Natalia Shalginskikh
472-NJ	Brca1ΔC mouse with a new mutation in the Brca1 gene Abstract	Neil Johnson	Tatiana Venkova
475-WK	Mouse Models of cystathionine beta-synthase (cbs) deficiency Abstract	Warren Kruger	Tatiana Venkova
513-JT	Lck-MyrAkt2 transgenic mice. Mice with constitutively activate Akt2 expressed in immature thymic cells, which develop a high incidence of spontaneous thymic lymphomas Abstract 1 Abstract 2	Joseph Testa	Tatiana Venkova
514-JT	Lck-Dlx5 transgenic mice. Mice that over-express Dlx5 in immature thymic cells, which develop a high incidence of spontaneous thymic lymphomas. Abstract	Joseph Testa	Tatiana Venkova
515-JT	Lck-MyrAkt2;Lck-Dlx5 mice. Mice with constitutively activate Akt2 and overexpression of Dlx5 in immature thymic cells, which develop a very high incidence of spontaneous thymic lymphomas. Abstract	Joseph Testa	Tatiana Venkova
523-DW	H2t-/- mice Abstract	David Wiest	Natalia Shalginskikh
533-JT	Tp53L/L:PtenL/L mouse model (conditional, with whole body homozygously floxed alleles of Tp53 and Pten) Abstract	Joseph Testa	Tatiana Venkova